VIARTIS

 

 

 

 

 

PARKINSON'S DISEASE NEWS

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21st July 2010 - New review

CABERGOLINE - A REVIEW OF THE DOPAMINE AGONIST

Cabergoline is also known by the brand names Dostinex and Cabaser. Cabergoline is a dopamine agonist that primarily stimulates the D2 receptor activity and has a very long half-life [1]. Besides being used for the treatment of Parkinson's Disease, cabergoline is also used for the treatment of hyperprolactinemia, and also exerts anti-depressant effects [2]. For more information got to Dostinex and Cabaser.

When cabergoline was compared to the use of L-dopa for Parkinson's Disease : motor complications, such as dyskinesia occurred less frequently [3], symptoms overall were worse [4], some symptom scores apart from motor disability were better [3], off time was reduced [5] [6], there were greater side effects [3] [4] [7], including nausea, vomiting, dyspepsia, gastritis, dizziness, postural hypotension, and peripheral oedema [8]. When cabergoline was added to the use of L-dopa : symptoms improved [9] [10] [11] [12] [13] [14] but not by much [13], there was a small reduction in off time [3] [12] [13] [15] [16], L-dopa dose could be reduced [3] [5], and side effects increased [10] [11] [13]. Cabergoline was found to be slightly better or similar than the use of bromocriptine [15] [17].

Cabergoline is associated with the risk of valvular heart disease [18], valvular regurgitation [19] [20] [21] [22] [23] [24], and worsens contrast sensitivity [25]. For more current news go to Parkinson's Disease News.

 

E-MAIL NOTIFICATION : If you would like to be notified by e-mail when any new research, news reports, new books, or new resources are added to Parkinson's Disease News,  please merely e-mail [email protected] with the message "subscribe".  No form of identity is required.  E-mail addresses are not used for any other purpose.

Parkinson's Disease News details all significant new research, news reports, new books, and new resources concerning Parkinson's Disease and those medical disorders that often coincide with Parkinson's Disease. It is compiled from an analysis of  all newly published research, news reports, new clinical trials, all newly published books, and new web sites. A summary and analysis of the new research are provided,  as well as links to the complete abstracts and news reports

                                    

 

    Back to PARKINSON'S DISEASE 

 
 
©2006-2010  Viartis
 
2015-11-08 09:32:35
 
[email protected]